Diagnostic, Prognostic, and Mechanistic Biomarkers of Diabetes Mellitus-Associated Cognitive Decline
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Cognitive dysfunctions such as mild cognitive impairment (MCI), Alzheimer’s disease (AD), and other forms of dementia are recognized as common comorbidities of type 2 diabetes mellitus (T2DM). Currently, there are no disease-modifying therapies or definitive clinical diagnostic and prognostic tools for dementia, and the mechanisms underpinning the link between T2DM and cognitive dysfunction remain equivocal. Some of the suggested pathophysiological mechanisms underlying cognitive decline in diabetes patients include hyperglycemia, insulin resistance and altered insulin signaling, neuroinflammation, cerebral microvascular injury, and buildup of cerebral amyloid and tau proteins. Given the skyrocketing global rates of diabetes and neurodegenerative disorders, there is an urgent need to discover novel biomarkers relevant to the co-morbidity of both conditions to guide future diagnostic approaches. This review aims to provide a comprehensive background of the potential risk factors, the identified biomarkers of diabetes-related cognitive decrements, and the underlying processes of diabetes-associated cognitive dysfunction. Aging, poor glycemic control, hypoglycemia and hyperglycemic episodes, depression, and vascular complications are associated with increased risk of dementia. Conclusive research studies that have attempted to find specific biomarkers are limited. However, the most frequent considerations in such investigations are related to C reactive protein, tau protein, brain-derived neurotrophic factor, advanced glycation end products, glycosylated hemoglobin, and adipokines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Dementia prevention, intervention, and care: 2020 report of the Lancet Commission
Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., Brayne, C., Burns, A., Cohen-Mansfield, J., Cooper, C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30367-6 · Cited by 10,430 · cited 2×
“Multiple studies also revealed that appropriate management of diabetes patients resulted in fewer vascular comorbidities and lowered the risk of dementia progression [63].”
BackgroundRetractedAlzheimer disease in the United States (2010–2050) estimated using the 2010 census
Hebert, L. E., Weuve, J., Scherr, P. A., & Evans, D. A. (2013) · Neurology · doi:10.1212/wnl.0b013e31828726f5 · Cited by 2,642 · cited 1×
“Alzheimer’s disease (AD) is the most common cause of dementia, affecting 60–70% of individuals aged 65 years or older [2].”
BackgroundAdvanced Glycation End Products: Sparking the Development of Diabetic Vascular Injury
Goldin, A., Beckman, J. A., Schmidt, A. M., & Creager, M. A. (2006) · Circulation · doi:10.1161/circulationaha.106.621854 · Cited by 2,261 · cited 16×
“Advanced glycation end products (AGEs) are a complex and heterogeneous group of compounds produced by the non-enzymatic modification of tissue proteins by physiologically reduced sugars [4].”
BackgroundInfluentialRisk of dementia in diabetes mellitus: a systematic review
Biessels, G. J., Staekenborg, S., Brunner, E., Brayne, C., & Scheltens, P. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70284-2 · Cited by 2,187
Inflammation: the link between insulin resistance, obesity and diabetes
Dandona, P. (2004) · Trends in Immunology · doi:10.1016/j.it.2003.10.013 · Cited by 2,170
Pendlebury, S. T., & Rothwell, P. M. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70236-4 · Cited by 1,853 · cited 1×
“In the general population, it was expected that 20% of the post-stroke population would develop dementia, and the risk of dementia increases by 3% per year after a stroke [66].”
BackgroundSmall vessel disease: mechanisms and clinical implications
Wardlaw, J. M., Smith, C., & Dichgans, M. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30079-1 · Cited by 1,777
Dyslipidemia in obesity: Mechanisms and potential targets
Klop, B., Elte, J., & Cabezas, M. (2013) · Nutrients · doi:10.3390/nu5041218 · Cited by 1,665 · cited 3×
“Dyslipidemia refers to unhealthy high levels of triglycerides and/or low-density lipoprotein (LDL) and low levels of high-density lipoprotein (HDL) [64].”
BackgroundCortisol levels during human aging predict hippocampal atrophy and memory deficits
Lupien, S. J., de Leon, M., de Santi, S., Convit, A., Tarshish, C., Nair, N. P. V., Thakur, M., McEwen, B. S., Hauger, R. L., & Meaney, M. J. (1998) · Nature Neuroscience · doi:10.1038/271 · Cited by 1,653
Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implications
Biessels, G. J., & Despa, F. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0048-7 · Cited by 1,454
CSF markers for incipient Alzheimer's disease
Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291
Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus
Whitmer, R. A. (2009) · JAMA · doi:10.1001/jama.2009.460 · Cited by 1,128 · cited 2×
“[24] Longitudinal cohort study 16,667 diabetes patients; mean age of 65 years ICD- 9-CM code ICD-9-CM codes A history of severe hypoglycemic episodes was associated with a greater risk of dementia”
BackgroundThe stress system in the human brain in depression and neurodegeneration
Swaab, D. F., Bao, A.-M., & Lucassen, P. J. (2005) · Ageing Research Reviews · doi:10.1016/j.arr.2005.03.003 · Cited by 984
Glucose Levels and Risk of Dementia
Crane, P. K., Walker, R., Hubbard, R. A., Li, G., Nathan, D. M., Zheng, H., Haneuse, S., Craft, S., Montine, T. J., Kahn, S. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215740 · Cited by 929
Rivera, E. J., Goldin, A., Fulmer, N., Tavares, R., Wands, J. R., & de la Monte, S. M. (2005) · Journal of Alzheimer s Disease · doi:10.3233/jad-2005-8304 · Cited by 723 · cited 2×
“This observation suggests that insulin may play a significant role in cognition by regulating cerebrocortical activity and brain metabolism and, most likely, by controlling the production of the neurotransmitter acetylcholine [88,89].”
BackgroundXue, M., Xu, W., Ou, Y.-N., Cao, X.-P., Tan, M.-S., Tan, L., & Yu, J.-T. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2019.100944 · Cited by 715 · cited 3×
“9-fold higher risk for cognitive dysfunction [5], including AD, with a relative risk (RR) of 1.”
BackgroundInfluentialStrachan, M. W. J., Deary, I. J., Ewing, F. M. E., & Frier, B. M. (1997) · Diabetes Care · doi:10.2337/diacare.20.3.438 · Cited by 529
Diabetes in Midlife and Cognitive Change Over 20 Years: A Cohort Study
Rawlings, A. M., Sharrett, A. R., Schneider, A. L. C., Coresh, J., Albert, M., Couper, D., Griswold, M., Gottesman, R. F., Wagenknecht, L. E., Windham, B. G., et al. (2014) · Annals of Internal Medicine · doi:10.7326/m14-0737 · Cited by 447
Altered Insulin Signaling in Alzheimer’s Disease Brain – Special Emphasis on PI3K-Akt Pathway
Gabbouj, S., Ryhänen, S., Marttinen, M., Wittrahm, R., Takalo, M., Kemppainen, S., Martiskainen, H., Tanila, H., Haapasalo, A., Hiltunen, M., et al. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00629 · Cited by 401 · cited 1×
“Furthermore, the impaired insulin-PI3K-Akt signaling observed in the AD brain enhances glycogen synthase kinase-3β, increasing the tau protein’s phosphorylation [92,93].”
BackgroundDefining the relationship between hypertension, cognitive decline, and dementia: a review
Walker, K. A., Power, M. C., & Gottesman, R. F. (2017) · Current Hypertension Reports · doi:10.1007/s11906-017-0724-3 · Cited by 394
Modifiable pathways in Alzheimer’s disease: Mendelian randomisation analysis
Larsson, S. C., Traylor, M., Malik, R., Dichgans, M., Burgess, S., & Markus, H. S. (2017) · BMJ · doi:10.1136/bmj.j5375 · Cited by 382
Palta, P., Schneider, A. L. C., Biessels, G. J., Touradji, P., & Hill-Briggs, F. (2014) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617713001483 · Cited by 364 · cited 1×
“The domains of information processing speed, attention and concentration, executive functioning, and working memory are most affected among people with diabetes [6].”
BackgroundBrain aging, Alzheimer's disease, and mitochondria
Swerdlow, R. H. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.08.012 · Cited by 306 · cited 1×
“The essential factor that causes neurodegenerative diseases is aging [76].”
BackgroundDiabetes mellitus and Alzheimer's disease: GSK-3β as a potential link
Zhang, Y., Huang, N.-Q., Yan, F., Jin, H., Zhou, S.-Y., Shi, J.-S., & Jin, F. (2018) · Behavioural Brain Research · doi:10.1016/j.bbr.2017.11.015 · Cited by 301
Feinkohl, I., Aung, P. P., Keller, M., Robertson, C. M., Morling, J. R., McLachlan, S., Deary, I. J., Frier, B. M., Strachan, M. W. J., Price, J. F., et al. (2014) · Diabetes Care · doi:10.2337/dc13-1384 · Cited by 266
Hassing, L. B. (2004) · Age and Ageing · doi:10.1093/ageing/afh100 · Cited by 249
Wium-Andersen, I. K., Osler, M., Jørgensen, M. B., Rungby, J., & Wium-Andersen, M. K. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0259 · Cited by 182
Age of onset of hypertension and risk of dementia in the oldest‐old: The 90+ Study
Corrada, M. M., Hayden, K. M., Paganini-Hill, A., Bullain, S. S., DeMoss, J., Aguirre, C., Brookmeyer, R., & Kawas, C. H. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.09.007 · Cited by 176
Low BDNF is associated with cognitive deficits in patients with type 2 diabetes
Zhen, Y. F., Zhang, J., Liu, X. Y., Fang, H., Tian, L. B., Zhou, D. H., Kosten, T. R., & Zhang, X. Y. (2013) · Psychopharmacology · doi:10.1007/s00213-012-2942-3 · Cited by 126
Associations of White Matter Hyperintensities with Cognitive Decline: A Longitudinal Study
Wang, Y.-L., Chen, W., Cai, W.-J., Hu, H., Xu, W., Wang, Z.-T., Cao, X.-P., Tan, L., Yu, J.-T., & Initiative, A. D. N. (2020) · Journal of Alzheimer’s Disease · doi:10.3233/jad-191005 · Cited by 92
Feinkohl, I., Keller, M., Robertson, C. M., Morling, J. R., Williamson, R. M., Nee, L. D., McLachlan, S., Sattar, N., Welsh, P., Reynolds, R. M., et al. (2013) · Diabetes Care · doi:10.2337/dc12-2241 · Cited by 69 · cited 2×
“Moreover, the Edinburgh Type 2 Diabetes Study found that with prior stroke, markers of subclinical macrovascular stress, including higher plasma levels of the natriuretic peptide NT-proBNP, and increased carotid intima-media thickness were associated with a steeper cognitive decline in patients who were diagnosed with…”
BackgroundTrento, M., Raballo, M., Trevisan, M., Sicuro, J., Passera, P., Cirio, L., Charrier, L., Cavallo, F., & Porta, M. (2012) · Acta Diabetologica · doi:10.1007/s00592-011-0275-z · Cited by 60 · cited 1×
“[81] reported that despite an increase in depression prevalence in diabetic patients (20.”
BackgroundHan, E., Han, K.-D., Lee, B.-W., Kang, E. S., Cha, B.-S., Ko, S.-H., & Lee, Y.-H. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab860 · Cited by 41 · cited 1×
“8 for those who had two or more episodes [29].”
Background
Cited by
Yang, C., Zhang, H., Ma, Z., Fan, Y., Xu, Y., Tan, J., Tian, J., Cao, J., Zhang, W., Huang, G., et al. (2024) · Journal of Diabetes · doi:10.1111/1753-0407.70029 · Cited by 11
“5,6 Mild cognitive impairment (MCI) is characterized by loss or decline of memory and language deterioration.”
Metadata
- Authors
- Ehtewish, H., Arredouani, A., & El-Agnaf, O.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-05-30
- Volume
- 23
- Issue
- 11
- Pages
- 6144
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W4282011314
- Cited by
- 175
- References
- 34
- FWCI
- 19.20
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.